Fig. 1 · Structure

Documents & Downloads

LY2119620

Cat. No. A14217 CAS 886047-22-9

M2/M4 AChR agonist

LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors.

In Stock

Publications for LY2119620

1 publication citing this product

  1. Shimrit Hazan, .et al. , Biochem Pharmacol, 2024, Sep:227:116421 PMID: 38996933

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

LY2119620 binds the extracellular allosteric vestibule above iperoxo in active M2 and M4 muscarinic receptor complexes. Structural comparisons show local pocket contraction and aromatic contacts involving Tyr177/Trp422 in M2 and Phe186/Trp435 in M4. These observations come from engineered, agonist-bound receptor complexes. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
M2 muscarinic acetylcholine receptor
M4 muscarinic acetylcholine receptor

LY2119620 Research Summary

This section summarizes 5 in vitro studies and 1 in vivo study of LY2119620 from 5 published references.

LY2119620 In Vitro Studies

LY2119620 modulation depends on the signaling endpoint. In M2-expressing HEK293T cells, it increased ACh and iperoxo potency, while high concentrations enhanced maximal β-arrestin-2 recruitment and reduced maximal Gαqi-linked IP-1 responses. In a separate purified M2/GoA assay, 100 μM LY2119620 reduced agonist-stimulated GTP turnover. [3]

In isolated mouse ventricular cardiomyocytes, 10 μM LY2119620 combined with 10 μM carbachol increased RyR2 Ser-2808 phosphorylation relative to carbachol alone. This result concerns a combination treatment in isolated cells. [4]

M2 receptor structure with iperoxo and LY2119620

Biochemical assay · Purified engineered human M2 receptor stabilized by Nb9-8; iperoxo-bound structures with and without LY2119620. [1]

LY2119620 occupied the extracellular vestibule above iperoxo. Its binding produced local pocket contraction and a Trp422 rotamer change, with few changes elsewhere.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LY2119620 position and contactsStructural observation Extracellular allosteric vestibule above iperoxo; aromatic stacking with Tyr177 (ECL2) and Trp422 (7.35).[1]
Comparison with active receptor lacking modulatorStructural comparison Slight vestibule contraction and Trp422 rotamer change; few differences outside the vestibule.[1]

Literature-Reported Treatment Conditions

Treatment concentration
500 μM LY2119620 in crystallization overlay
Method
Lipidic cubic phase crystallization
Co-treatment
Iperoxo-bound receptor; Nb9-8 stabilization
Reported limits
Structural preparation concentration, not a potency estimate. Salt form and stock solvent not established.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Fig. 5; Extended Data Figs. 5–6; Extended Data Table 1; Online Methods: crystallization samples, crystallization and refinement

LY2119620 position and contacts: X-ray crystallography; ligand density and structural comparison. — Fig. 5b,c; Extended Data Fig. 5a; Allosteric modulation

Comparison with active receptor lacking modulator: Paired iperoxo-bound structures. — Extended Data Fig. 6a–d and caption; Allosteric modulation

M4 receptor–Gi complex with iperoxo and LY2119620

Biochemical assay · Engineered human M4 receptor with N-terminal BRIL fusion and ICL3 deletion, complexed with Gi and scFv16. [2]

LY2119620 bound the extracellular allosteric pocket, stacked between Phe186 and Trp435. The vestibule was more compact than in the iperoxo-only complex.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LY2119620 binding pose at M4Cryo-EM structural observation Aromatic interactions with Phe186 (ECL2) and Trp435 (7.35); piperazine orientation differs from M2.[2]

Literature-Reported Treatment Conditions

Treatment concentration
337 μM LY2119620; 400 μM iperoxo added during final concentration
Method
Purified receptor–Gi complex for cryo-EM
Co-treatment
Iperoxo, Gi and scFv16
Reported limits
Structural preparation concentrations; no EC50 inferred. LY2119620 salt and stock solvent not established.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Figs. 1b,d and 2b–e; Results on binding/activation; Methods: construct design and M4R–Gi–scFv16 complex purification

LY2119620 binding pose at M4: Cryo-EM and comparison with iperoxo-only complex. — Fig. 2b,c,e; Results: Iperoxo and LY2119620 binding pockets in M4R

Pathway-dependent modulation of M2 signaling

Cell-based study · HEK293T cells expressing M2 receptor: hybrid Gαqi/IP-One and PathHunter β-arrestin-2 assays. [3]

LY2119620 increased agonist potency. At high concentrations it increased maximal β-arrestin-2 recruitment while reducing maximal IP-1 responses to ACh and iperoxo; modulator-only low-efficacy agonism was also observed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Agonist potency and maximal Gαqi-linked IP-1 responseConcentration-response comparison Agonist potency increased; high LY2119620 concentrations reduced maximal IP-1 responses for ACh and iperoxo.[3]
Maximal β-arrestin-2 recruitmentConcentration-response comparison Maximal recruitment increased for ACh and iperoxo at high LY2119620 concentrations.[3]

Literature-Reported Treatment Conditions

Treatment concentration
LY2119620 0.1–100 μM; ACh or iperoxo concentration-response series
Exposure duration
30 min modulator preincubation, followed by 90 min with agonist
Method
IP-One HTRF and PathHunter assays
Vehicle
Vehicle control; composition not specified in read assay methods
Co-treatment
ACh or iperoxo; modulator-only responses also shown
Reported limits
Methods list agonist ranges separately by assay. Exact per-condition n and SI Table 1 values not extracted. Fig. 1 caption: 3–14 independent experiments, mean ± SEM; methods: 4–8 IP-1 and 3–5 arrestin experiments, each in duplicate.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Fig. 1a,e–l; Results: Functional differences; Methods: G-protein IP-1 assay and β-arrestin recruitment assay

Agonist potency and maximal Gαqi-linked IP-1 response: IP-One HTRF; reference ACh maximum 100%, vehicle 0%. — Fig. 1e,f,i,j; functional Results; IP-1 methods

Maximal β-arrestin-2 recruitment: PathHunter complementation; basal activity 0%, reference ACh maximum 100%. — Fig. 1g,h,k,l; functional Results; β-arrestin recruitment methods

Purified-protein test of G-protein activation

Biochemical assay · Purified M2 receptor and heterotrimeric GoA; GTPase-Glo assay. Construct description is not fully reconciled between Results and linked preparation methods. [3]

At 100 μM, LY2119620 reduced agonist-stimulated GTP turnover relative to ACh or iperoxo alone in the purified-protein assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Agonist-stimulated GTP turnoverAgonist plus modulator versus agonist alone Reduced turnover with 100 μM LY2119620 for ACh and iperoxo.[3]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM LY2119620; 100 μM ACh or 10 μM iperoxo; M2R 1 μM, GoA 0.5 μM
Exposure duration
90 min at room temperature (22–25°C)
Method
GTPase-Glo residual-GTP assay
Co-treatment
ACh or iperoxo; respective agonist-only controls and GoA-only reference
Reported limits
LY2119620 stock vehicle not specified. Single modulator concentration; no IC50 derived. Results call the purified receptor wild-type, while the referenced preparation method describes ICL3 truncation. No full-length/wild-type receptor claim is made.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Fig. 1m and caption; Results: Functional differences; Methods: GTPase Glo assay

Agonist-stimulated GTP turnover: Luminescent residual-GTP assay with GoA-only reference. — Fig. 1m; functional Results; GTPase Glo methods

Carbachol-associated RyR2 phosphorylation in native cardiomyocytes

Cell-based study · Isolated wild-type mouse ventricular cardiomyocytes; isolation methods describe 3–6-month-old mice of either sex. [4]

LY2119620 plus carbachol increased RyR2 Ser-2808 phosphorylation relative to carbachol alone. This does not establish LY2119620 monotherapy activity or intact-animal benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RyR2 Ser-2808 phosphorylation normalized to total RyR2Combination versus carbachol alone Increased; p < 0.01 versus carbachol as stated in Fig. 1 caption.[4]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM LY2119620 with 10 μM carbachol
Method
Isolated cardiomyocyte treatment followed by Western blot
Co-treatment
Carbachol; untreated and carbachol-only controls
Reported limits
Exposure duration and vehicle not specified for Fig. 1 in read Western blot methods/caption. LY2119620 supplier, salt and purity not established.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Fig. 1A–D; first Results paragraph; Methods: cardiomyocyte isolation and Western blot analyses

RyR2 Ser-2808 phosphorylation normalized to total RyR2: Phospho-specific/total RyR2 blot; GAPDH control. Caption: median ± S.D.; WT n = 5–7 mice, minimum 3 experiments/group. — Fig. 1C,D and caption; first Results paragraph; Western blot methods

LY2119620 In Vivo Studies

In a four-week guinea-pig form-deprivation model, repeated intravitreal LY2119620 produced more negative refraction and greater axial length than vehicle. Week-4 spherical equivalent was −4.85 ± 1.01 D versus −3.05 ± 0.69 D, and axial length was 8.49 ± 0.13 mm versus 8.35 ± 0.06 mm (mean ± SD). Retinal Kir3.4 protein expression did not differ significantly from vehicle. These findings are specific to this ocular model and do not establish M2-selective causality. [5]

LY2119620 drug arm in form-deprivation myopia

Animal study · Three-week-old male tricolor guinea pigs; initial weight 150–180 g; right-eye form deprivation; n = 15 assigned per drug group. [5]

Repeated intravitreal LY2119620 was associated with more negative refraction and greater axial length than vehicle after four weeks. Retinal Kir3.4 protein did not differ significantly from vehicle, limiting a simple protein-downregulation explanation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Week-4 spherical-equivalent refractionMean ± SD LY2119620: −4.85 ± 1.01 D; vehicle: −3.05 ± 0.69 D.[5]
Week-4 axial lengthMean ± SD LY2119620: 8.49 ± 0.13 mm; vehicle: 8.35 ± 0.06 mm.[5]
Retinal Kir3.4 protein expression versus vehicleReported statistical comparison No statistically significant difference (P = 0.092).[5]

Conditions shared by the study groups

Route
Intravitreal
Frequency
Every 4 days, starting day 1 of modeling
Treatment course
Four-week form-deprivation experiment
Vehicle
10% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Form deprivation plus LY2119620
100 μM LY2119620; 10 μL injection volume
Form deprivation plus DMSO vehicle, n = 15 assigned; untreated form-deprivation and normal groups also included.More negative refraction and greater axial length at week 4 versus vehicle (values in measurements). Kir3.4 protein comparison was not significant.[5]
Form deprivation plus LY2119620
Model: Three-week-old male tricolor guinea pigs; initial weight 150–180 g; right-eye form deprivation; n = 15 assigned per drug group.
Reported limits: Salt and purity not specified; no concentration gradient, systemic exposure or comprehensive safety evaluation.
Methods and source locations

Compound reported in the paper: LY2119620; Compound label in the paper: LY

Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.

Table 3; actual Fig. 5A,B,J,K; drug-arm Results; Methods: Animals and Grouping, Biological Measurements, statistical analyses

Week-4 spherical-equivalent refraction: Retinoscopy; actual Table 3 cells, not curve estimates. Assigned n = 15/group. — Table 3: SE, D; FD + LY2119620 and FD + DMSO rows, 4 Wks column; Fig. 5A

Week-4 axial length: A-mode ultrasound; actual Table 3 cells. Assigned n = 15/group. — Table 3: AL, mm; FD + LY2119620 and FD + DMSO rows, 4 Wks column; Fig. 5B

Retinal Kir3.4 protein expression versus vehicle: Western blot/gray-value analysis. General methods: at least 3 independent experiments; condition-specific biological n not assigned. — Results: M2 Receptor Mediated Regulation of Potassium Concentration by Kir3.4, protein paragraph; actual Fig. 5J,K

Form deprivation plus LY2119620 · Methods: Animals and Grouping, drug-intervention sentence; Table 3; actual Fig. 5A,B,J,K

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 886047-22-9
Applications M2/M4 AChR agonist
Formula C19H24ClN5O3S
Molecular Weight 437.94
Synonyms LY-2219620
SMILES
CC1=C2C(=C(SC2=NC(=C1Cl)OCC(=O)N3CCN(CC3)C)C(=O)NC4CC4)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 77 mg/mL (175.82 mM)
Water Insoluble
Ethanol Warmed: 9 mg/mL (20.55 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY2119620 Research References

  1. [1] Kruse AC, Ring AM, Manglik A, et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature (2013). PMID: 24256733 DOI: 10.1038/nature12735 Source material
  2. [2] Wang J, Wu M, Chen Z, et al. The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands Nature communications (2022). PMID: 35606397 DOI: 10.1038/s41467-022-30595-y Source material
  3. [3] Xu J, Wang Q, Hübner H, et al. Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor Nature communications (2023). PMID: 36690613 DOI: 10.1038/s41467-022-35726-z Source material
  4. [4] Baine S, Thomas J, Bonilla I, et al. Muscarinic-dependent phosphorylation of the cardiac ryanodine receptor by protein kinase G is mediated by PI3K-AKT-nNOS signaling The Journal of biological chemistry (2020). PMID: 32580946 DOI: 10.1074/jbc.ra120.014054 Source material
  5. [5] Zhou H, Zhou G, Yang Q, et al. Evidence for M2 Muscarinic Receptor Antagonist Delay of Myopia Development Through Activation of Kir3.4 Channel in the Retina of Guinea Pigs Investigative ophthalmology & visual science (2025). PMID: 40600764 DOI: 10.1167/iovs.66.9.5 Source material

Publications

1 publication citing this product

  1. Shimrit Hazan, .et al. , Biochem Pharmacol, 2024, Sep:227:116421 PMID: 38996933

Added to your cart

View Cart Checkout
Loading...